We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.22B
1-Year Est. Return 242.83%
This Fund
S&P 500
This Quarter Est. Return
-11.56%
1 Year Est. Return
+242.83%
3 Year Est. Return
+1,579.88%
5 Year Est. Return
+1,852.28%
10 Year Est. Return
–
AUM
$375M
AUM Growth
-$22.1M
Cap. Flow
+$63.9M
Cap. Flow %
17.03%
Top 10 Hldgs %
64.63%
Holding
62
New
5
Increased
7
Reduced
14
Closed
5

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$30.6M
2
NKTX icon
Nkarta
NKTX
+$10.9M
3
LYRA
LYRA THERAPEUTICS INC
LYRA
+$9.68M
4
HLVX
HilleVax
HLVX
+$9.06M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$8.95M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$3.17M
2
RXRX icon
Recursion Pharmaceuticals
RXRX
+$1.81M
3
TIL icon
Instil Bio
TIL
+$1.44M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$1.37M
5
SWTX
SpringWorks Therapeutics
SWTX
+$1.35M

Sector Composition

Rank Sector Weight
1 Healthcare 97.54%
2 Financials 2.13%
3 Miscellaneous 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$90.3M 24.07%
5,161,888
+570,000
+12% +$8.95M
NKTX icon
2
Nkarta
NKTX
$206M
$35.3M 9.42%
2,868,035
+833,333
+41% +$10.9M
SRRK icon
3
Scholar Rock
SRRK
$6.01B
$25.2M 6.73%
4,598,828
+4,259,217
+1,254% +$30.6M
LENZ
4
LENZ Therapeutics
LENZ
$130M
$23.3M 6.2%
1,208,473
+55,244
+5% +$1.23M
ACLX
5
DELISTED
Arcellx
ACLX
$19.2M 5.13%
1,063,835
+64,108
+6% +$827K
FMTX
6
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$10.8M 2.88%
1,565,526
– –
LYRA
7
DELISTED
LYRA THERAPEUTICS INC
LYRA
$10M 2.68%
+35,545
New +$9.68M
ACRS icon
8
Aclaris Therapeutics
ACRS
$783M
$9.72M 2.59%
696,171
-98,000
-12% -$1.37M
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.72M 2.59%
1,010,051
-252,500
-20% -$3.17M
ICPT
10
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$8.85M 2.36%
640,688
– –
STRO icon
11
Sutro Biopharma
STRO
$259M
$8.73M 2.33%
167,558
– –
RAIN
12
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$8.68M 2.31%
1,560,652
-10,727
-0.7% -$36.8K
HLVX
13
DELISTED
HilleVax
HLVX
$8.34M 2.22%
+762,577
New +$9.06M
TIL icon
14
Instil Bio
TIL
$48.7M
$8.26M 2.2%
89,414
-10,184
-10% -$1.44M
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
$8.25M 2.2%
1,693,736
-190,360
-10% -$1.22M
PEPG icon
16
PepGen
PEPG
$201M
$6.46M 1.72%
+651,050
New +$7.26M
IMCR icon
17
Immunocore
IMCR
$1.63B
$6.01M 1.6%
160,963
– –
ZYME icon
18
Zymeworks
ZYME
$1.88B
$5.15M 1.37%
970,987
– –
JYAC
19
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$5.01M 1.34%
507,041
– –
IOBT
20
DELISTED
IO Biotech
IOBT
$4.71M 1.26%
1,008,437
-112,000
-10% -$686K
VRNA
21
DELISTED
Verona Pharma
VRNA
$4.66M 1.24%
1,111,112
– –
JANX icon
22
Janux Therapeutics
JANX
$993M
$4.4M 1.17%
360,414
-51,457
-12% -$609K
DICE
23
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$3.93M 1.05%
253,466
+25,000
+11% +$430K
EYPT icon
24
EyePoint Inc
EYPT
$297M
$3.78M 1.01%
480,000
– –
DAWN
25
DELISTED
Day One Biopharmaceuticals
DAWN
$3.52M 0.94%
196,425
-6,075
-3% -$62.7K
1
2 3

Similar funds

MWA
Monograph Wealth Advisors Manhattan Beach, California $1.22B AUM 24.22% 1-Year Est. Return
SFP
Shepherd Financial Partners Winchester, Massachusetts $1.22B AUM 28.54% 1-Year Est. Return
OCM
Once Capital Management New York $1.22B AUM 87.6% 1-Year Est. Return
TCM
Tributary Capital Management Omaha, Nebraska $1.22B AUM 44.12% 1-Year Est. Return
TCM
Thames Capital Management Roseland, New Jersey $1.22B AUM 391.75% 1-Year Est. Return
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
GGI
Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return
SL
Salomon & Ludwin Richmond, Virginia $1.22B AUM 19.42% 1-Year Est. Return

Samsara BioCapital's Q2 2022 Portfolio in Review

As of Q2 2022, Samsara BioCapital held 62 positions worth $375M, down 5.6% from $397M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Samsara BioCapital deployed $63.9M of net new capital in Q2 2022, opening 5 new positions and adding to 7 existing holdings. Its largest new stake was LYRA THERAPEUTICS INC: 35,545 shares worth $10M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $3.17M trimmed.

  • Samsara BioCapital's largest Q2 2022 buy was LYRA THERAPEUTICS INC: 35,545 shares worth $10M.
  • Samsara BioCapital added most to Scholar Rock in Q2 2022, an estimated $30.6M increase.
  • Samsara BioCapital's biggest Q2 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $3.17M.
  • Samsara BioCapital fully exited Odonate Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $925K.
  • Samsara BioCapital's ten largest holdings make up 65% of its $375M portfolio in Q2 2022.
  • Samsara BioCapital opened 5 new positions and closed 5 in Q2 2022.
  • Samsara BioCapital's portfolio value fell 5.6% quarter-over-quarter to $375M.

Based on Samsara BioCapital's 13F filing for Q2 2022, filed 15 Aug 2022.